June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

February 14, 2017

Retreatment of Psoriasis with Taltz after Interruption in Therapy Is Effective, Study Suggests

News

Retreatment with Taltz (ixekizumab), after the end of initial treatment led to a relapse, restored response in most psoriasis patients, according to a study. Another finding was that uninterrupted treatment for ... Read more

February 9, 2017

Stelara Remains Effective Psoriasis Treatment Long After Others Fizzle, Study Shows

News

Janssen Biotech’s Stelara (ustekinumab) remains an effective treatment for severe psoriasis long after other therapies have lost their punch, a study shows. The research, “Biologic drug survival in Israeli psoriasis patients,” ... Read more

February 7, 2017February 7, 2017

Remicade Use Up to 4 Weeks Before Joint Surgery Does Not Increase Infection Risk, Study Says

News

Treating patients with Remicade (infliximab) until up to four weeks before a joint operation does not increase the risk of infection compared to halting the treatment up to 8-12 weeks ... Read more

January 31, 2017January 31, 2017

Biosimilar to Humira, Amgevita, Recommended for Approval in EU

News

A biosimilar candidate to Humira (adalimumab), Amgevita (ABP 501), was recommended for EU approval by the Committee for Medicinal Products for Human Use (CHMP) as a treatment of moderate to severe chronic ... Read more

January 26, 2017

FDA Approves Generic Version of Topicort Spray for Plaque Psoriasis

News

The U.S. Food and Drug Administration (FDA) has approved Perrigo’s generic version of Topicort (desoximetasone topical spray, 0.25%) to treat plaque psoriasis, the company announced. Topicort, owned by Taro Pharmaceuticals US, is a ... Read more

January 24, 2017

Cosentyx Is Better, Cheaper Therapy Than Humira for US Psoriatic-arthritis Patients

News

Cosentyx (secukinumab, Novartis) is a better and cheaper treatment for psoriatic arthritis in the United States than Humira (adalimumab, AbbVie), a study has concluded. The research, “Comparison of Secukinumab Vs ... Read more

January 19, 2017January 19, 2017

Coherus Reports Positive 24-Week Trial Results for Humira Biosimilar in Psoriasis Patients

News

Coherus BioSciences recently reported positive 24-week results from the second part of a three-part Phase 3 clinical trial comparing biosimilar CHS-1420, a therapy candidate for plaque psoriasis, to Humira (adalimumab). The results from ... Read more

January 17, 2017January 17, 2017

Possibly Pivotal Phase 3 Trial Shows Combo Lotion, IDP-118, Ably Treats Plaque Psoriasis

News

Treatment with IDP-118 (halobetasol propionate and tazarotene), a lotion developed by Valeant Pharmaceuticals, successfully improved the signs and symptoms of plaque psoriasis, according to the results of a second and confirmatory ... Read more

January 12, 2017January 12, 2017

Psoriasis May Be Associated with Liver Disease, Research Shows

News

People with psoriasis also may develop non-alcoholic fatty liver disease (NAFLD), a disorder that causes severe liver complications, researchers reported. The study, “Relationship Between Psoriasis And Non-Alcoholic Fatty Liver Disease,” ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata